EQUITY RESEARCH - ANALYST MEETING



FSSIA ESG rating



BANGKOK DUSIT MEDICAL SERVICES

THAILAND / HEALTH CARE SERVICES

BDMS TB



TARGET PRICE THB34.50 THB26.50

CLOSE **UP/DOWNSIDE** +30.2% TP vs CONSENSUS +0.7%

Key takeaways from analyst meeting

Highlights


- ราได้รับข้อมูลเชิงบวกเล็กน้อยจากที่ประชุมนักวิเคราะห์หลังผลประกอบการ 3Q23 ของ BDMS
- ผู้บริหารปรับเพิ่มเป้าการเติบโตของรายได้ปี 2023 เป็น 9-10% จาก 6-8% พร้อม EBITDA margin ที่ 24% (เทียบกับ 24% ใน 9M23) ซึ่งหมายความถึงการเติบโตของ รายได้ที่ 9-13% y-y เป็น 26.0-26.9พัน ลบ. ใน 4Q23 (เทียบกับ 26.7พัน ลบ. ในปี 3Q23)
- รายได้จากผู้ป่วยจากต่างประเทศโตต่อเนื่องในเดือน ต.ค. โดยมีการเติบโตอยู่ที่ 19% y-y (เทียบกับ 19% ในเดือน ต.ค.). รายได้จากผู้ป่วยชาวตะวันออกกลางชะลอตัวมาโต 31% y-y (เทียบกับ 41% y-y ใน 3Q23) แต่รายได้จากผู้ป่วยจาก CLMV โตเร่งตัวขึ้น เป็น 13% y-y (เทียบกับ 12% y-y ใน 3Q23)
- คาดตัวเลขสมาชิกประกันสังคมลงทะเบียนจะโตจาก 790k ในปี 2023 เป็นกว่า 1.0ล้าน ในปี 2025 ปัจจุบันโรงพยาบาลทั้ง 9 แห่งได้เข้าร่วมโครงการประกันสังคมและน่าจะมี โรงพยาบาลเข้าร่วมเพิ่มอีก 3 แห่งในช่วง 2 ปีข้างหน้า
- ผู้ป่วยชาวจีนกระโดดเพิ่มจากอันดับที่ 9 เป็นที่ 4 ในแง่สัดส่วนรายได้ (1.9% ของ รายได้รวมในช่วง 9M23) พร้อมอัตราการเติบโตที่ 49% y-y ในช่วง 9M23 โดยได้ ปัจจัยหนุนจากผู้ป่วยต่างชาติที่อาศัยอยู่ในประเทศไทย
- ปัจจุบัน Movenpick Wellness Resort มีอัตราการเข้าพัก (OCC rate) อยู่ที่ 60% ในขณะที่กำไรสุทธิมีจุดคุ้มทุนอยู่ที่ 70% รายได้จากลูกค้าจากต่างประเทศคิดเป็น ประมาณ 40% BDMS วางแผนเพิ่มบริการทางคลินิกให้แก่โรงแรมอาทิเช่น การ ทดสอบการนอนหลับหรือการตรวจสุขภาพเพื่อดึงดูดลูกค้าที่ต้องการใช้บริการด้าน สุขภาพจากต่างประเทศเพิ่มขึ้นในปีหน้า

Recommendation

BDMS มีการซื้อขายที่ 28x ของค่า 2024E P/E ซึ่งต่ำกว่าค่าเฉลี่ย 5 ปีย้อนหลังที่ 34x ราคาหุ้นปรับตัวลดลงแล้ว 9% นับตั้งแต่ตันปีนี้สวนทางกับกำไรซึ่งทำสถิติสูงสุดใหม่ใน 3Q23 เพราะฉะนั้นเราจึงมองว่านี่เป็นโอกาสในการซื้อหัน

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	92,968	100,315	108,779	116,421
Net profit	12,606	13,469	15,295	16,843
EPS (THB)	0.79	0.85	0.96	1.06
vs Consensus (%)	-	(0.1)	4.2	6.5
EBITDA	22,933	24,415	26,856	29,091
Recurring net profit	12,606	13,469	15,295	16,843
Core EPS (THB)	0.79	0.85	0.96	1.06
EPS growth (%)	63.0	6.8	13.6	10.1
Core P/E (x)	33.4	31.3	27.5	25.0
Dividend yield (%)	1.9	1.9	1.9	2.2
EV/EBITDA (x)	18.9	17.5	15.6	14.1
Price/book (x)	4.7	4.4	4.1	3.8
Net debt/Equity (%)	9.2	1.3	(7.0)	(14.4)
ROE (%)	14.5	14.5	15.4	15.8




Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(2.8)	(6.2)	(8.6)
Relative to country (%)	(1.5)	1.3	4.2
Mkt cap (USD m)			12,010
3m avg. daily turnover (USD m)			39.4
Free float (%)			70
Major shareholder		Thai N\	/DR (14%)
12m high/low (THB)		3	1.00/25.00
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates




Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: Non-Covid Thai patient revenue, quarterly



Source: BDMS

Exhibit 3: Utilisation rate



Source: BDMS

Exhibit 5: Strong trend of international patient growth






Exhibit 2: International patient revenue, quarterly




Source: BDMS

Exhibit 4: EBITDA margin trend, quarterly



Source: BDMS

Exhibit 6: Revenue contribution by nationality as of 9M23



Source: BDMS Source: BDMS

Financial Statements

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	75,514	92,968	100,315	108,779	116,421
Cost of goods sold	(49,462)	(58,329)	(62,761)	(67,590)	(72,059)
Gross profit	26,052	34,638	37,555	41,189	44,362
Other operating income	-	-	-	-	-
Operating costs	(15,029)	(17,655)	(19,351)	(20,712)	(21,934)
Operating EBITDA	17,345	22,933	24,415	26,856	29,091
Depreciation	(6,321)	(5,950)	(6,211)	(6,378)	(6,663)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	11,023	16,984	18,204	20,478	22,428
Net financing costs	(655)	(552)	(558)	(469)	(394)
Associates	21	42	26	28	31
Recurring non-operating income	26	50	34	38	42
Non-recurring items	200	0	0	0	0
Profit before tax	10,594	16,481	17,680	20,047	22,075
Tax	(2,103)	(3,227)	(3,531)	(4,004)	(4,409)
Profit after tax	8,490	13,254	14,149	16,043	17,666
Minority interests	(554)	(648)	(680)	(748)	(823)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	7,936	12,606	13,469	15,295	16,843
Non-recurring items & goodwill (net)	(200)	0	0	0	0
Recurring net profit	7,736	12,606	13,469	15,295	16,843
Per share (THB)					
Recurring EPS *	0.49	0.79	0.85	0.96	1.06
Reported EPS	0.50	0.79	0.85	0.96	1.06
DPS	0.80	0.50	0.50	0.51	0.58
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	9.3	23.1	7.9	8.4	7.0
Operating EBITDA (%)	16.1	32.2	6.5	10.0	8.3
Operating EBIT (%)	29.3	54.1	7.2	12.5	9.5
Recurring EPS (%)	28.0	63.0	6.8	13.6	10.1
Reported EPS (%)	10.0	58.8	6.8	13.6	10.1
Operating performance					
Gross margin inc. depreciation (%)	34.5	37.3	37.4	37.9	38.1
Gross margin exc. depreciation (%)	42.9	43.7	43.6	43.7	43.8
Operating EBITDA margin (%)	23.0	24.7	24.3	24.7	25.0
Operating EBIT margin (%)	14.6	18.3	18.1	18.8	19.3
Net margin (%)	10.2	13.6	13.4	14.1	14.5
Effective tax rate (%)	20.3	19.6	20.0	20.0	20.0
Dividend payout on recurring profit (%)	164.7	63.0	59.0	52.8	54.5
Interest cover (X)	16.9	30.8	32.7	43.8	57.0
Inventory days	16.3	14.7	14.8	14.8	14.9
Debtor days	39.4	38.5	38.1	35.2	32.9
Creditor days	40.1	39.1	41.4	41.4	41.7
Operating ROIC (%)	10.6	15.8	16.2	18.4	20.4
ROIC (%)	8.5	12.7	13.1	14.8	16.3
ROE (%)	9.0	14.5	14.5	15.4	15.8
ROA (%)	6.7	10.1	10.1	10.9	11.2
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
Thai patient revenue	58,500	67,286	68,038	73,507	79,081
Thai patient revenue International patient revenue	58,500 12,841	67,286 21,248	68,038 27,623	73,507 30,385	79,081 32,208

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Financial Statements

Bangkok Dusit Medical Services

Cash Flow (THB m) Year Ending Dec					
Recurring net profit	2021	2022	2023E	2024E	2025E
	7,736	12,606	13,469	15,295	16,843
Depreciation	6,321	5,950	6,211	6,378	6,663
Associates & minorities	0,021	5,550	0,211	0,570	0,005
Other non-cash items	997	1,275	680	748	823
Change in working capital	(980)	720	940	1,072	966
Cash flow from operations	14,074	20,551	21,300	23,493	25,295
Capex - maintenance	(4,235)	(14,953)	(6,019)	(6,527)	(6,985)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(58)	(386)	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(4,293)	(15,340)	(6,019)	(6,527)	(6,985)
Dividends paid	(12,738)	(7,943)	(7,946)	(8,081)	(9,177)
Equity finance	0	0	0	0	0
Debt finance	(5,416)	4,764	(2,000)	(500)	(500)
Other financing cash flows	75	299	0	0	0
Cash flow from financing	(18,079)	(2,880)	(9,946)	(8,581)	(9,677)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	(8,298)	2,330	5,335	8,385	8,633
Free cash flow to firm (FCFF)	10,509.69	5,842.84	15,981.37	17,627.65	18,977.14
Free cash flow to equity (FCFE)	4,439.73	10,273.66	13,280.96	16,465.99	17,810.13
Per share (THB)					
FCFF per share	0.66	0.37	1.01	1.11	1.19
FCFE per share	0.28	0.65	0.84	1.04	1.12
Recurring cash flow per share	0.95	1.25	1.28	1.41	1.53
Balance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Tangible fixed assets (gross)	142,630	155,412	161,431	167,958	174,943
Less: Accumulated depreciation	(59,725)	(63,503)	(69,714)	(76,092)	(82,755)
Tangible fixed assets (net)	82,905	91,909	91,717	91,866	92,188
Intangible fixed assets (net)	18,828	19,160	19,160	19,160	19,160
Long-term financial assets	-	-	-	-	-
Invest. in associates & subsidiaries	1,600	1,986	1,986	1,986	1,986
Cash & equivalents	12,641	14,972	20,307	28,691	37,325
A/C receivable	9,131	10,484	10,484	10,484	10,484
Inventories	2,005	2,211	2,387	2,584	2,761
Other current assets	624	132	142	154	165
Current assets	24,401	27,799	33,320	41,914	50,735
Other assets	720	689	689	689	689
Total assets	128,454	141,543	146,872	155,615	164,758
Common equity	83,845	89,879	95,402	102,615	110,282
Minorities etc.	3,920	3,834	4,514	5,262	6,086
Total shareholders' equity	87,765	93,713	99,916 21,062	107,878	116,368
Long term debt Other long-term liabilities	18,753 9,442	23,062 10,032	10,032	20,562 10,032	20,062 10,032
Long-term liabilities	28,196	33,094	31,094	30,594	30,094
A/C payable	5,035	6,176	6,668	7,217	7,711
Short term debt	76	532	532	532	532
Other current liabilities	7,382	8,028	8,663	9,394	10,053
Current liabilities	12,493	14,736	15,862	17,143	18,296
Total liabilities and shareholders' equity	128,454	141,543	146,872	155,615	164,758
Net working capital	(657)	(1,377)	(2,316)	(3,388)	(4,354)
Invested capital	103,396	112,367	111,235	110,313	109,669
* Includes convertibles and preferred stock which is being		,	,	,	,
· .					
Per share (THB)					
Book value per share	5.28	5.66	6.00	6.46	6.94
Tangible book value per share	4.09	4.45	4.80	5.25	5.73
Financial strength					
Net debt/equity (%)	7.1	9.2	1.3	(7.0)	(14.4)
Net debt/total assets (%)	4.8	6.1	0.9	(4.9)	(10.2)
Current ratio (x)	2.0	1.9	2.1	2.4	2.8
CF interest cover (x)	7.8	19.6	24.8	36.1	46.2
Valuation	2021	2022	2023E	2024E	2025E
Recurring P/E (x) *	54.4				25.0
NECULLING F/E (X)	70.9	33.4 43.5	31.3 40.7	27.5 35.8	25.0 32.6
	70.9 53.1	43.5 33.4	31.3	27.5	25.0
Recurring P/E @ target price (x) *	DO. I		1.9	27.5 1.9	25.0
Recurring P/E @ target price (x) * Reported P/E (x)		1 0			
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	3.0	1.9 4 7			
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	3.0 5.0	4.7	4.4	4.1	3.8
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	3.0 5.0 6.5	4.7 6.0	4.4 5.5	4.1 5.0	3.8 4.6
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	3.0 5.0 6.5 24.9	4.7 6.0 18.9	4.4 5.5 17.5	4.1 5.0 15.6	3.8 4.6 14.1
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	3.0 5.0 6.5	4.7 6.0	4.4 5.5	4.1 5.0	3.8 4.6

Sources: Bangkok Dusit Medical Services; FSSIA estimates

Bangkok Dusit Medical Serv (BDMS TB)

Exhibit 7: FSSIA ESG score implication

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
****	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 8: ESG – peer comparison

	FSSIA			Dome	stic ratings					- Global	ratings			Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Υ	Υ	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

 $Sources: \underline{\textbf{SETTRADE.com}}; \textbf{FSSIA's compilation}$

Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based		_	91	92	98	94	96	209
GHG Scope 3		_	_	_	_	_	_	_
Carbon per unit of production		_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	_	_	1	2	2	2	3	5
Total waste	_	_	6	7	7	5	9	13
Waste recycled	_	_	0	1	1	0	1	2
Waste sent to landfills	_	_	_	_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes							
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	_	_	82	82	82	82	83	83
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	Yes							
Anti-bribery ethics policy	Yes							
Health and safety policy	Yes							
Lost time incident rate - employees	_	_	0	0	0	0	0	
Total recordable incident rate - employees	_	_	2	2	2	1	1	
Training policy	Yes							
Fair remuneration policy	No							
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct	_	_	18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance								
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	
No. of non-executive directors on board	9	7	6	8	9	9	9	
Company conducts board evaluations	Yes							
No. of board meetings for the year	13	13	14	12	13	12	12	12
Board meeting attendance pct	95	94	98	97	98	98	97	100
Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No							
Age of the youngest director	45	42	43	44	45	46	47	48
Age of the oldest director	83	84	85	86	87	88	89	90
No. of executives / company managers	4	5	5	5	6	7	5	
No. of female executives	1	1	1	2	1	2	2	
Executive share ownership guidelines	No	No.						
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	
Audit committee meetings	10	9	10	7	10	6	6	
Audit committee meetings Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	100
No. of ID on compensation committee	3	3	3	2	2	2	2	
·	3	1	4	4	3	4	4	
No. of compensation committee meetings								
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	
No. of nomination committee meetings	3	1 100	4	4	3	4	4	100
Nomination meeting attendance % Sustainability governance	100	100	100	100	100	100	100	100

 $Sources: Bloomberg; FSSIA's \ compilation$

Disclaimer for ESG scoring

ESG score	Methodolog	IY .			Rating					
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the ann	ed on the comp nual S&P Globa	ransparent, rules-based co panies' Total Sustainability Il Corporate Sustainability nies within each industry a	Scores resulting Assessment (CSA).	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.					
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing bu Candidates r 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the par trading of the shareholders, ome key disque ependent direct related to CG,	ity in Environmental and Sinsparency in Governance or eemptive criteria, with two board members and execute and combined holding mulalifying criteria include: 1) ors and free float violation; social & environmental imparnings in red for > 3 years	, updated annually. vo crucial conditions: cutives; and 2) free st be >15% of paid- CG score of below ; 3) executives' pacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight at maximum, and no cap for number of stocks.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD, w	in sustainable developme vith support from the Stock are from the perspective	Exchange of	Scores are rated in six categories: 5 for Excellent (90-100), 4 for Very Good (80-89), 3 for Good (70-79), 2 for Fair (60-69), 1 for Pass (60-69), and not rated for scores below 50. Weightings include: 1) the rights; 2) and equitable treatment of shareholders (weight 25% combined); 3) the role of stakeholders (25%); 4) disclosure & transparency (15%); and 5) board responsibilities (35%).					
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the assessment the meeting advance circul rights can be e transparency a	e incorporated and sufficiently e CG compone criteria cover A date (45%), an lation of sufficient exercised. The se and verifiability; and	hich shareholders' rights a into business operations a disclosed. All form importants to be evaluated annual (SM procedures before the dafter the meeting (10%), information for voting; and 2) found assesses 1) the ease of a day openness for Q&A. The tentain discussion issues, resolution.	and information is ant elements of two ally. The e meeting (45%), at (The first assesses 1) acilitating how voting attending meetings; 2) third involves the	The scores are classified into four categories: 5 for Excellent (100), 4 for Very Good (90-99), 3 for Fair (80-89), and not rated for scores below 79.					
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies of Declaration of Certification, ir managers and	nt of key control c Certification is eciding to become Intent to kick off a ncluding risk asse	hecklist include corruption ols, and the monitoring and good for three years. e a CAC certified member start an 18-month deadline to submi ssment, in place of policy and blishment of whistleblowing ch stakeholders.)	developing of t by submitting a tit the CAC Checklist for control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					
Morningstar Sustainalytics	based on an risk is unman regulatory filing information, co	assessment of naged. Sources gs, news and other	k rating provides an overa f how much of a company' to be reviewed include corpore er media, NGO reports/website , ESG controversies, issuer fee ws.	s exposure to ESG ate publications and es, multi-sector	A company's ESG risk rating score is the sum of unmanaged risk. The more risk is unmanaged, the higher ESG risk is scored. NEGL Low Medium High Severe 0-10 10-20 20-30 30-40 40+					
ESG Book	positioned to the principle helps explair over-weighting	o outperform ov of financial ma n future risk-ad	ustainable companies that er the long term. The meth teriality including informati justed performance. Mater h higher materiality and rel	nodology considers on that significantly riality is applied by	The total ESG score is calculated as a weighted sum of the features scores using materiality-based weights. The score is scaled between 0 and 100 with higher scores indicating better performance.					
MSCI					relevant ESG risks and opportunities. It uses a rules-based methodology to isks and how well they manage those risks relative to peers.					
	AAA	8.571-10.000								
	AA	7.143-8.570	Leader:	leading its industry in n	nanaging the most significant ESG risks and opportunities					
	Α	5.714-7.142								
	BBB	4.286-5.713	Average:	a mixed or unexception industry peers	nal track record of managing the most significant ESG risks and opportunities relative to					
	ВВ	2.857-4.285								
	В	1.429-2.856	Laggard:	lagging its industry has	sed on its high exposure and failure to manage significant ESC ricks					
	ccc	0.000-1.428	Layyaru.	lagging its industry bas	sed on its high exposure and failure to manage significant ESG risks					
Moody's ESG solutions	believes that	t a company int	•	its business model ar	objectives in the definition and implementation of their strategy policies. It and relatively outperforming its peers is better positioned to mitigate risks and					
Refinitiv ESG rating	based on pu	blicly available	and auditable data. The s	core ranges from 0 to	GG performance, commitment and effectiveness across 10 main themes, 100 on relative ESG performance and insufficient degree of transparency in a satisfactory; >50 to 75 = good; and >75 to 100 = excellent.)					
S&P Global			e is a relative score measunt the same industry classif		formance on and management of ESG risks, opportunities, and impacts nges from 0 to 100.					
Bloomberg	ESG Score		score is based on Bloomb	erg's view of ESG fin	gregated Environmental, Social and Governance (ESG) performance. The ancial materiality. The score is a weighted generalized mean (power mean) ned by the pillar priority ranking. Values range from 0 to 10; 10 is the best.					
Bloomberg	ESG Disclos	sure Score			mberg ESG score. The score ranges from 0 for none to 100 for disclosure of G data reported publicly, and not the performance on any data point.					

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation



GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION


Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
24-Nov-2020	BUY	27.00	24-Jun-2021	BUY	29.00	06-Oct-2022	BUY	33.00
11-May-2021	BUY	28.00	19-Apr-2022	BUY	31.00	08-Jan-2023	BUY	34.50

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 26.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 17-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.